Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
Will Karachi schools remain open tomorrow?
- 14 hours ago
Pakistan’s pharma exports reach $457m
- 12 hours ago
IAEA chief reports progress in Iran nuclear talks
- 12 hours ago
French parliament topples Bayrou government after just 9 months
- 12 hours ago
Fatal collision in Karachi: Motorcyclist dies after being hit by speeding trailer
- 13 hours ago
Five family members killed in car-trailer collision on Haripur Road
- 2 hours ago
Flood in Jalalpur: Urban dam in danger, several settlements affected
- an hour ago
TCL gives parents a monochrome mode to combat kids’ phone addiction
- 6 hours ago
The Southern takeover of American culture
- 4 hours ago
52 more Palestinians martyred in Israeli worst bombing
- 2 hours ago
'He changed for the better of the game': How Jim Harbaugh has evolved as Chargers coach
- 5 hours ago
The 'invisible fight' that has inspired The Fighting Nerds' viral success
- 5 hours ago
